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Abstract
Sexually transmitted infections (STIs) are caused by a wide spectrum 
of bacteria, viruses and parasites. These agents can be easily trans-
mitted by direct genital or oral sexual contact. Recently, the World 
Health Organization (WHO), reported that more than 1 million STIs 
are acquired every day worldwide. Each year, there are an estimated 
357 million new infections with one of the following four STIs: chla-
mydia, gonorrhea, syphilis and trichomoniasis. There are few studies 
and official reports published on the prevalence of STIs in most Arab 
countries. However, a few recent studies showed indicate an increased 
prevalence of certain STIs in some Arab countries, and few data is 
available on their antimicrobial susceptibility.
Introduction
Gonorrhea is the second most prevalent bacterial 
sexually transmitted infection (STI) with a global es-
timated incidence of 78 million cases annually [1,2], 
with probably a large number of cases that remain 
unreported [2]. In the United States of America, N. 
gonorrhea is the second most commonly reported 
communicable disease, with more than 350,000 
cases reported annually [3]. A recent study from 
Saudi Arabia reported that nongonococcal urethri-
tis, trichomoniasis, and HIV were the most com-
monly reported STIs in the Kingdom of Saudi Arabia 
over the period 2005-2012 , and the study showed 
that gonococcal urethritis accounted for 4.4% of 
the total STI cases [4].
Obligate pathogenic organisms of STIs such as 
gonorrhea and syphilis can be recognized clinically 
and confirmed by rapid laboratory test in men and 
women. Whereas, other potential bacterial patho-
gens of STIs represented by Chlamydia trachomatis, 
Mycoplasma genitalium and Ureaplasma urealyti-
cum are among the most prevalent agents found 
in the genital tract of humans [5-6]. These organ-
isms are more difficult to detect and to prove their 
presence the actual cause of genital infections, since 
they can contribute to asymptomatic and symptom-
atic clinical diseases alone or in association with N. 
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gonorrhea [5-7]. Prompt and accurate treatment of 
STIs is essential measurement to cure patients and 
prevents their complications . In addition, rapid de-
tection of positive cases of STIs will help to control 
and prevent the spread of their harmful agents in 
the communities. It is important to mention that 
there is no available vaccine against any type of STIs.
Clinical manifestations of N. gonorrhea 
infections
The majority of urethral infections caused by N. 
gonorrhea among men produce symptoms that 
require medical examination [8]. Among women, 
gonorrhea does not produce recognizable symp-
toms until complications occur [9]. Because gono-
coccal infections among women are frequently as-
ymptomatic, the Centers for Disease Control and 
Prevention (CDC/USA) recommended that clinicians 
screen all sexually active women, including those 
who are pregnant, for gonorrhea infection if they 
are at any increased risk [10]. In general, risk factors 
of gonorrhea infections include age younger than 
25 years, a previous gonorrhea infection, other STIs, 
and new or multiple sexual partners [8-10].
 In Western countries, 10 to 30 % of patients with 
gonorrhea will have a concomitant Chlamydia infec-
tion [6,11-12]. The disease is associated with high 
morbidity and socioeconomic consequences and re-
mains a public health problem worldwide. N. gonor-
rhea can also infect other mucosal surfaces, includ-
ing the pharynx, rectum and conjunctiva, but may 
rarely invade the bloodstream, causing disseminated 
infection [8,11,13]. In women, the primary gonococ-
cal infection is in the endocervix, with concomitant 
urethral infection, and it is frequently asymptomatic, 
but if the infection causes symptoms, the most com-
mon is purulent vaginal discharge , which is a result 
of endocervicitis [8,10-11]. Gonorrhea infections do 
not cause vaginitis, but other concomitant infec-
tions may produce vaginal findings [8]. Ascending 
infection may occur in 10–20% of infected women 
and can result in acute pelvic inflammatory disease 
(PID) or salpingitis that may manifest as endometritis, 
and tubo-ovarian abscess, all of which can lead to 
scarring, ectopic pregnancy, infertility, and chronic 
pelvic pain [8,13-14]. In men, gonococcus is known 
to cause urethritis, which is rarely complicated by 
infections of other parts of the genital tract [11,13]. 
Unlike women, men with urogenital infections are 
usually symptomatic. The normal incubation period 
is two to six days after exposure, and symptoms 
include purulent penile discharge and dysuria. The 
possibility always remains of untreated gonorrhea in 
men leading to prostatitis, epididymitis, epididymo-
orchitis, urethral stricture, and infertility [14,15-16]. 
Rectal infection with N. gonorrhoeae may occur 
through direct inoculation by receptive anal inter-
course and is typically seen in homosexual males 
but can also appear in women. In addition, patients 
often do not experience symptoms (two thirds of 
patients), except for possible occurrences of anal 
pruritus, painless rectal discharge, and tenesmus. 
Pharyngeal infections caused by N. gonorrhoeae 
usually occur after orogenital exposure; symptoms 
are mild or absent [11,13]. Adult ocular gonococ-
cal infection is very rare, with transmission usually 
being by autoinoculation or direct inoculation from 
the genital secretions of an infected partner [17]. 
Disseminated infection is rare but it can occur in 1 
to 3 % of adults who have gonorrhea. It can oc-
cur in both sexes with higher frequency in women 
[8,11-12 ]. Symptoms of disseminated infection can 
range from slight joint pain, a few skin lesions, and 
no fever to overt polyarthritis and a high fever [11-
12]. Disseminated gonorrhea may also present as 
bacterial endocarditis and meningitis; yet, the inci-
dences of these presentations have declined with 
the introducing of antibiotic therapy [11]. During the 
neonatal period and the first year of life, gonorrhea 
infections can cause neonatal conjunctivitis (oph-
thalmia neonatorum), pharyngitis, rectal infections, 
and, in rare cases, pneumonia [8,11]. Preadolescent 
children most commonly contract gonococcal infec-
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tions through sexual abuse [8]. Rapid diagnosis and 
administration of antimicrobial therapy are the main 
measurement to reduce and control of gonorrhea 
infection in the community and prevent its complica-
tions in infected persons [3,18] .
Laboratory Diagnosis 
Specimen collection
The specimen collection method depends on the 
testing technique used in a laboratory and the age, 
sex and sexual orientation of the patient. Specimens 
should be collected with dacron or rayon swabs be-
cause calcium alginate may be toxic to gonococci. 
Fatty acids inhibit the growth of gonococci; therefore, 
cotton swabs that do not list acceptable manufactur-
er specifications should not be used [19]. To minimize 
the inhibitory effects of unknown substances in the 
specimen, the swabs should be inoculated directly 
onto growth medium or placed in swab transport 
medium immediately after sampling [20].
Gram-stain and culture
Until the late 1980s, laboratory diagnosis of gon-
orrhea was limited to gram stain and bacterial isola-
tion. Gram staining may be performed directly on 
exudates from several sites, such as the male urethra, 
cervix, rectum, synovial fluid, eye discharge, vagina 
in prepubertal girls, skin lesions, and cerebrospinal 
fluid. The presence of intracellular gram- negative 
kidney-shaped diplococci in polymorphonuclear leu-
kocytes on microscopy suggests the diagnosis of 
a gonococcal infection [8,12]. The gram stain is a 
rapid tool and has comparable sensitivity to bacte-
rial culture for symptomatic urethral gonorrhea in 
men. However, it is relatively insensitive for speci-
mens collected from women and from extragenital 
sites where the specificity of gram stain may also 
be affected by the presence of commensal Neisse-
ria species [20]. The primary specimens should be 
inoculated onto nonselective chocolate agar and 
selective agar (Thayer-Martin) containing antimicro-
bial agents that inhibit the growth of commensal 
bacteria and fungi. The inoculated plates should be 
incubated at 35°C to 37°C in a moist atmosphere 
enriched with CO2 (3% to 7%)[19]. After 18 h to 
24 hours culture should be used as the inoculum for 
additional tests. Plates should not be incubated for 
longer than 48 h because most old cultures would 
not survive storage conditions. Autolysis may occur 
during prolonged incubation, and growth from agar 
plates becomes difficult to suspend in solutions.
Confirmation of isolates
Several Neisseria and related species may be mis-
identified as N. gonorrhea unless appropriate differ-
ential tests are performed, especially in specimens 
obtained for direct smear or isolates from  endocer-
vical secretions of women. Therefore, it is essential 
to confirm N. gonorrhea  isolates by biochemical 
tests: N gonorrhea can be differentiated from other 
Neisseria species, Moraxella species, Kingella spe-
cies and other commensals based on its ability to 
grow on appropriate selective and nonselective me-
dia, produce acid from glucose, maltose,
lactose, sucrose and fructose, reduce nitrate, pro-
duce polysaccharide from sucrose and exhibit DNase 
production. The Rapid Identification Method-Neis-
seria (Remel Inc, USA) is a commercially available 
rapid acid production test that compares well with 
the conventional method, but may also not differ-
entiate between N gonorrhea and N cinerea [21].
Chromogenic enzyme substrates
These tests are based on the presence of pre-
formed chromogenic enzyme in the culture and, 
thus, require a heavy inoculum of the organism 
grown on selective medium to permit rapid specia-
tion of isolates. 
Evaluation of eight methods for identification of 
pathogenic Neisseria species: Neisseria-Kwik, RIM-
N, Gonobio-Test, Minitek, Gonochek II, GonoGen, 
Phadebact Monoclonal GC OMNI Test, and Syva 
MicroTrak Test [21]. 
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Coagglutination tests
Coagglutination tests can be performe on prima-
ry culture and, therefore, confirmed results can be 
obtained one day earlier than tests that require sub-
culturing from primary culture plates, by using mo-
lecular techniques [22], or the Maldi Tof technique 
[23]. There is no specific and sensitive serological 
test available to detect recent gonococcal infections 
through the demonstration of N. gonorrhea-specific 
antibodies or antigens in patients’ sera [19].
Molecular detection Methods
Over the last 20 years, nucleic acid amplification 
methods (NAATs) have gradually replaced tradition-
al methods for the detection of sexually transmit-
ted infections. NAAT technology comes with some 
important gains for diagnosis, increased sensitiv-
ity, and rapid result for screening of symptomatic 
and asymptomatic individuals using various clinical 
specimens [19]. However, NAAT tests have some 
technical problems. False-negative and false-posi-
tive results have been reported using various tests. 
Additionally, NAAT methods can facilitate detec-
tion of C. trachomatis, N. gonorrhoeae, M. genita-
lium and T. vaginalis [24]. Single detection systems 
or dual detection tests for C. trachomatis and N. 
gonorrhea are now commercially available The hy-
bridization assays include the Gen- Probe PACE II 
(Gen-Probe, USA) and the Digene Hybrid Capture 
II assays (Digene Corp., USA) [25]. These assays use 
a specific oligonucleotide probe to hybridize directly 
to N. gonorrhea nucleic acid present within a speci-
men . Reported sensitivity and specificity values of 
the hybridization assays showed that these may be 
below that of bacterial culture [25]. Several com-
mercial N. gonorrhea NAATs are available since 10 
years, and make use of different technologies: Poly-
merase Chain Reaction (PCR) (Roche Diagnostics, 
USA), Transcription-Mediated Amplification (TMA) 
(Gen-Probe, USA), Strand Displacement Amplifica-
tion (SDA) (Becton Dickinson, USA), and the Ligase 
Chain Reaction (LCR) (Abbott Laboratories, USA) 
[12]. Each of these assays has used a unique N. 
gonorrhea gene target [25]. Multiplex qualitative 
real-time PCR assay that detects C. trachomatis and 
N. gonorrhea and contains an internal control has 
been developed. A real-time PCR assay has the ad-
vantage of reducing the detection time of regular 
PCR procedures [24]. In addition to the commercial 
assays, numerous in house N. gonorrhoeae NAAT 
assays have also been described. Gene targets for 
in-house PCR assays have included the ORF1, CppB, 
OMPIII, Opa genes as well as the porA pseudogene 
[24].
There are several advantages of N. gonorrhea 
NAATs; first, they offer improved sensitivity com-
pared with bacterial culture. The increased sensi-
tivity of NAATs makes them particularly suitable 
for screening, enabling accurate diagnosis of both 
symptomatic and asymptomatic gonococcal infec-
tions, which is critical to the control of the disease 
[24]. Second, specimens collected for NAATs do 
not require the organism to be viable for detection 
and so require less stringent transport conditions 
compared with those collected for bacterial culture. 
Finally, NAATs can be used effectively on nonin-
vasive specimens such as urine and self-collected 
specimens [6, 24 ]. N. gonorrhea NAATs do have 
some limitations; these include the typical problems 
associated with the use of NAAT protocols, such as 
high cost, carryover contamination, inhibition of the 
reaction, high quality control requirements, and the 
absence of antibiotic resistance data [25]. In addi-
tion, DNA amplification tests may not be suitable 
for test-of-cure because gonococcal DNA may be 
present for weeks after successful treatment of an 
infection [25]. 
Recommendation: The Centers for Disease Con-
trol and Prevention (CDC,USA) now promotes nu-
cleic acid amplification testing, also known as NAAT, 
as the preferred method to detect these STDs in 
men and women in its latest recommendations to 
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clinical laboratories [26]. The NAAT method detects 
the DNA genes of the bacteria causing the infec-
tion. It does this in part by amplifying or making 
numerous copies of the genetic material so that the 
detection system can identify the presence of the 
bacteria. It is theoretically able to detect as little as 
a single copy of bacterial nucleic acid in a sample 
taken from the individual tested [26].
Antimicrobial treatment
The widespread distribution of N. gonorrhea 
strains which are resistant to commonly and previ-
ously used antibiotics is a significant global public 
health problem, and it is a major threat to reducing 
the impact of STIs worldwide [27-31]. Recent studies 
from different continents reported increased antibi-
otic resistance to most previously used drugs such 
as penicillin, tetracycline and fluoroquinolones [31-
34]. Resistance to ciprofloxacin has reached 52.9% 
in Europe, 74.5% in Russia, 86.5% in the USA and 
93.8% in China [30-31]. Moreover, a meta-analysis 
conducted in China and a report from the French 
National Reference Centre (CNR) have described an 
important resistance rate to tetracycline (82.4% and 
86%, respectively) [32]. 
Few studies have recently reported on antibiotic 
resistance among N. gonorrhea isolates in Arab 
countries [35,36]. A study carried by Hamze et al., 
2016 [35], indicated that a significant increase in the 
prevalence of gonorrhea in Tripoli/ North of Leba-
non , a city suffering from a decline in the current 
socioeconomic situation with a high unemployment 
rate, extreme poverty and the influx of thousands 
of Syrian refugees. All their s N. gonorrhea trains 
were isolated from male patients . The study dem-
onstrated N. gonorrhea strains showed significant 
rates of resistance to quinolone, macrolide and tet-
racycline drugs, with a resistance prevalence rates of 
72.3% to nalidixic acid, 40.4% to ofloxacin, 38.3% 
to ciprofloxacin, 40.4% to azithromycin, 23.4% to 
tetracycline and 21.3% to minocycline [35]. While 
a recent study from Morocco reported that a to-
tal of 72 isolates were examined, and a significant 
resistance to tetracycline (92.8%) and ciprofloxacin 
(86.8%), which were used as first-line treatment in 
gonococcal infections in Morocco. However, no re-
sistance was found to spectinomycin, ceftriaxone or 
cefixime in all the isolates [36].
Currently, the treatment of gonococcal infections 
in many countries is limited to the use of third-
generation cephalosporins such as ceftriaxone 
and cefixime [22-26]. The results of a recent study 
showed that the gonococcal genotypes persisting 
in the population and fluctuated significantly within 
a 3 year period, with numerous other genotypes 
appearing or disappearing. Significant fluctuations 
in the most common genotypes accounted for the 
majority of observed increases in both ciprofloxa-
cin and penicillin resistance. Single-year genotypes 
contributed to ∼20% of ciprofloxacin and penicil-
lin resistance in each year. The study assumed that 
these changes determines N. gonorrhea antimicro-
bial resistance levels within the population [27].
It is important to note that some patients with 
gonococcal infection should be treated for possible 
C. trachomatis coinfection if chlamydia has not been 
ruled out [11]. For infections acquired via consen-
sual sexual activity, patients should be advised to be 
abstinent for at least one week after treatment to 
prevent reinfection. Patients should also be advised 
to contact their sexual partners and to encourage 
their treatment. This strategy greatly reduces the 
public health burden of gonococcal disease [11]. 
The epidemiology of antimicrobial resistance in 
N.gonorrhea has changed decisions about gonococ-
cal treatment recommendations because of shifts in 
antimicrobial resistance patterns in many countries 
over the world. The emergence of fluoroquinolone-
resistant N. gonorrhea in the United States prompted 
the CDC in 2007, to stop recommending fluoroqui-
nolones for treatment of gonorrhea, leaving cepha-
losporins as the only remaining class of antimicrobials 
available for treatment of gonorrhea in the United 
States [36]. Criteria for resistance to cefixime and cef-
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triaxone have not been defined by the Clinical and 
Laboratory Standards Institute (CLSI). However, iso-
lates with cefixime or ceftriaxone MICs ≥0.5 µg/mL 
are considered to have decreased susceptibility [37]. 
Because of the prevalence of tetracycline resistance 
among N. gonorrhea isolates worldwide, particu-
larly those with elevated cefixime MICs, the use of 
azithromycin as the second antimicrobial is preferred. 
However, decreased susceptibility of N. gonorrhea to 
cephalosporins and other antimicrobials is expected 
to continue; local and country surveillance for anti-
microbial resistance is essential for guiding therapy 
recommendations [38]. 
Recommendation
The new CDC guidelines recommend either the 
association of a cephalosporin with azithromycin or 
a higher ceftriaxone dose. Gonococcal strains with 
elevated MICs to cefixime also are likely to be resis-
tant to tetracyclines but susceptible to azithromycin 
in the United States. Consequently, only one regi-
men, dual treatment with ceftriaxone and azithro-
mycin, is recommended for treatment of gonorrhea 
[39]. However, in the case of azithromycin allergy, 
doxycycline (100 mg orally twice a day for 7 days) 
can be used in place of azithromycin as an alterna-
tive second antimicrobial drug when used in com-
bination with ceftriaxone or cefixime [39]. 
In conclusion, gonorrhea infection is still highly 
important public  health issue and should be con-
trolled by rapid  diagnostic methods and treated 
without any delay with effective antimicrobial drugs.
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